ArticleDiscover oncology2025
Intrahepatic cholangiocarcinoma patient with epidermal growth factor receptor exon 19 deletion unresponsive to Afatinib monotherapy: a case report.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe efficacy of epidermal growth factor receptor EGFR tyrosine kinase inhibitors in cholangiocarcinoma (CCA) patients is still unknown. Here, we report a 67-year-old CCA patient with EGFR exon 19 deletion receiving afatinib treatment. CASE DESCRIPTION: A 67-year-old male was referred to our hospital due to persistent abdominal pain for 3 months. Abdominal computed tomography showed a tumor with a diameter of 92 mm in the left liver with multiple intrahepatic metastases. Immunohistochemistry revealed that tumor cells were positive for CK7 and CK19, and negative for hepatocyte and CDX- 2. A pathological diagnosis of intrahepatic CCA was made. Since the patient declined standard chemotherapy, afatinib was administered as the first-line treatment. Upon disease progression, apatinib was introduced. Unfortunately, the patient ultimately succumbed to hepatic failure, with a total survival of 1.8 months.
conclusionIn this report, the CCA patient with EGFR exon 19 deletion was unresponsive to afatinib treatment. However, genetic testing may be still worthwhile for CCA to increase the possible treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.